CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries

View as:

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

Phase: N/A Priority: Normal

NCT ID: NCT03810144 Org: User:

Start: 10/22/18 End: 10/16/22 Due: 10/16/23

Clinical Follow-up of Pregnant Subjects Undergoing NIPT

Phase: N/A Priority: Normal

NCT ID: NCT04595201 Org: User:

Start: 10/13/20 End: 10/13/25 Due: 10/13/26

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Phase: N/A Priority: Normal

NCT ID: NCT02586389 Org: User:

Start: 10/13/15 End: 10/31/27 Due: 10/31/28

Compliant Analysis of Patient Samples and Data

Phase: N/A Priority: Normal

NCT ID: NCT04364503 Org: User:

Start: 03/17/18 End: 08/15/30 Due: 08/15/31

Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies

Phase: N/A Priority: Normal

NCT ID: NCT01597063 Org: User:

Start: 07/31/12 End: 12/31/15 Due: 12/31/16

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

Phase: N/A Priority: Normal

NCT ID: NCT06008457 Org: User:

Start: 04/17/23 End: 05/31/25 Due: 05/31/26

Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Phase: N/A Priority: Normal

NCT ID: NCT00971334 Org: User:

Start: 08/31/09 End: 12/31/11 Due: 12/31/12

Development of a NIPTT for Detecting Copy Number Variations

Phase: N/A Priority: Normal

NCT ID: NCT04774640 Org: User:

Start: 05/29/14 End: 04/30/18 Due: 04/30/19

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal

NCT ID: NCT03631225 Org: User:

Start: 06/25/19 End: 09/15/25 Due: 09/15/26

A Noninvasive Test for Fetal RHD Genotype

Phase: N/A Priority: Normal

NCT ID: NCT00871195 Org: User:

Start: 04/30/09 End: 04/30/12 Due: 04/30/13

Non-Invasive Screening for Fetal Aneuploidy

Phase: N/A Priority: Normal

NCT ID: NCT00847990 Org: User:

Start: 03/31/09 End: 08/31/11 Due: 08/31/12

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

Phase: N/A Priority: Normal

NCT ID: NCT01644513 Org: User:

Start: 07/31/12 End: 12/31/12 Due: 12/31/13

Evaluation of a Noninvasive Fetal RHD Genotyping Test

Phase: N/A Priority: Normal

NCT ID: NCT01054716 Org: User:

Start: 05/31/09 End: 11/30/10 Due: 11/30/11

Development of a Fetal Sex Assay From Maternal Whole Blood

Phase: N/A Priority: Normal

NCT ID: NCT00970047 Org: User:

Start: 06/30/08 End: 07/31/10 Due: 07/31/11

Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies

Phase: N/A Priority: Normal

NCT ID: NCT01021085 Org: User:

Start: 04/30/09 End: 09/30/11 Due: 09/30/12

Non-Invasive Preeclampsia Screening and Biobank

Phase: N/A Priority: Normal

NCT ID: NCT06643741 Org: User:

Start: 02/02/25 End: 07/01/26 Due: 07/01/27

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Phase: N/A Priority: Normal

NCT ID: NCT01880788 Org: User:

Start: 11/30/12 End: 08/31/15 Due: 08/31/16

Genetic Load and Phenotype in Aggressive AMD

Phase: N/A Priority: Normal

NCT ID: NCT01650948 Org: User:

Start: 07/31/12 End: 12/31/13 Due: 12/31/14

Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Phase: N/A Priority: Normal

NCT ID: NCT01429389 Org: User:

Start: 05/31/11 End: 03/31/26 Due: 03/31/27

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

Phase: N/A Priority: Normal

NCT ID: NCT01682382 Org: User:

Start: 08/31/12 End: 10/31/13 Due: 10/31/14

Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

Phase: N/A Priority: Normal

NCT ID: NCT01555346 Org: User:

Start: 03/31/12 End: 12/31/15 Due: 12/31/16

Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies

Phase: N/A Priority: Normal

NCT ID: NCT01052688 Org: User:

Start: 11/30/09 End: 08/31/21 Due: 08/31/22

Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test

Phase: N/A Priority: Normal

NCT ID: NCT01835483 Org: User:

Start: 05/31/13 End: 07/31/13 Due: 07/31/14

Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies

Phase: N/A Priority: Normal

NCT ID: NCT02226315 Org: User:

Start: 08/31/14 End: 09/30/15 Due: 09/30/16

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Phase: N/A Priority: Normal

NCT ID: NCT00770458 Org: User:

Start: 06/30/08 End: 12/31/09 Due: 12/31/10

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test	NCT03810144	Sequenom, Inc.	user2@example.com	None	2018-10-22	2022-10-16	2023-10-16	-	-	2025-07-14
Clinical Follow-up of Pregnant Subjects Undergoing NIPT	NCT04595201	Sequenom, Inc.	user2@example.com	None	2020-10-13	2025-10-13	2026-10-13	-	-	2025-07-14
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay	NCT02586389	Sequenom, Inc.	user2@example.com	None	2015-10-13	2027-10-31	2028-10-31	-	-	2025-07-14
Compliant Analysis of Patient Samples and Data	NCT04364503	Sequenom, Inc.	user2@example.com	None	2018-03-17	2030-08-15	2031-08-15	-	-	2025-07-14
Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies	NCT01597063	Sequenom, Inc.	user2@example.com	None	2012-07-31	2015-12-31	2016-12-31	-	-	2025-07-14
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit	NCT06008457	Sequenom, Inc.	user2@example.com	None	2023-04-17	2025-05-31	2026-05-31	-	-	2025-07-14
Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker	NCT00971334	Sequenom, Inc.	user2@example.com	None	2009-08-31	2011-12-31	2012-12-31	-	-	2025-07-14
Development of a NIPTT for Detecting Copy Number Variations	NCT04774640	Sequenom, Inc.	user2@example.com	None	2014-05-29	2018-04-30	2019-04-30	-	-	2025-07-14
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis	NCT03631225	Sequenom, Inc.	user2@example.com	None	2019-06-25	2025-09-15	2026-09-15	-	-	2025-07-14
A Noninvasive Test for Fetal RHD Genotype	NCT00871195	Sequenom, Inc.	user2@example.com	None	2009-04-30	2012-04-30	2013-04-30	-	-	2025-07-14
Non-Invasive Screening for Fetal Aneuploidy	NCT00847990	Sequenom, Inc.	user2@example.com	None	2009-03-31	2011-08-31	2012-08-31	-	-	2025-07-14
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients	NCT01644513	Sequenom, Inc.	user2@example.com	None	2012-07-31	2012-12-31	2013-12-31	-	-	2025-07-14
Evaluation of a Noninvasive Fetal RHD Genotyping Test	NCT01054716	Sequenom, Inc.	user2@example.com	None	2009-05-31	2010-11-30	2011-11-30	-	-	2025-07-14
Development of a Fetal Sex Assay From Maternal Whole Blood	NCT00970047	Sequenom, Inc.	user2@example.com	None	2008-06-30	2010-07-31	2011-07-31	-	-	2025-07-14
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies	NCT01021085	Sequenom, Inc.	user2@example.com	None	2009-04-30	2011-09-30	2012-09-30	-	-	2025-07-14
Non-Invasive Preeclampsia Screening and Biobank	NCT06643741	Sequenom, Inc.	user2@example.com	None	2025-02-02	2026-07-01	2027-07-01	-	-	2025-07-14
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD	NCT01880788	Sequenom, Inc.	user2@example.com	None	2012-11-30	2015-08-31	2016-08-31	-	-	2025-07-14
Genetic Load and Phenotype in Aggressive AMD	NCT01650948	Sequenom, Inc.	user2@example.com	None	2012-07-31	2013-12-31	2014-12-31	-	-	2025-07-14
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy	NCT01429389	Sequenom, Inc.	user2@example.com	None	2011-05-31	2026-03-31	2027-03-31	-	-	2025-07-14
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)	NCT01682382	Sequenom, Inc.	user2@example.com	None	2012-08-31	2013-10-31	2014-10-31	-	-	2025-07-14
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies	NCT01555346	Sequenom, Inc.	user2@example.com	None	2012-03-31	2015-12-31	2016-12-31	-	-	2025-07-14
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies	NCT01052688	Sequenom, Inc.	user2@example.com	None	2009-11-30	2021-08-31	2022-08-31	-	-	2025-07-14
Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test	NCT01835483	Sequenom, Inc.	user2@example.com	None	2013-05-31	2013-07-31	2014-07-31	-	-	2025-07-14
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies	NCT02226315	Sequenom, Inc.	user2@example.com	None	2014-08-31	2015-09-30	2016-09-30	-	-	2025-07-14
Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker	NCT00770458	Sequenom, Inc.	user2@example.com	None	2008-06-30	2009-12-31	2010-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance